Press Release

  • Press Release
  • No Likes

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand
ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus® Phase II Site Initiation Visit (SIV) at Ramathibodi Hospital, Faculty of Medicine, Mahidol University (TH001) in Thailand was successfully conducted on March 22, 2023. read more
  • Press Release
  • No Likes

ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results
ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results 150 150 Press Release
ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver high efficacy and low toxicity to improve health outcomes, today announced its financial and operating results for the fiscal year ended December 31, 2022. read more
  • Press Release
  • No Likes

ABVC BioPharma Provides 2023 Pipeline Update
ABVC BioPharma Provides 2023 Pipeline Update 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023 read more
  • Press Release
  • No Likes

ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has closed a funding agreement for gross proceeds of $3.175 million (the “Investment”) with Lind Global Fund II read more
  • Press Release
  • No Likes

ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus® 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that approval to initiate the Phase II study of its Vitargus® medical device, in Australia, was received from the Australian Therapeutic Goods Administration (TGA) read more
  • Press Release
  • No Likes

ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference 150 150 Press Release
ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Keith McBurnett, Professor of Psychiatry at the University of California San Francisco, read more

BACKGROUND

Leadership Team

MANAGEMENT
ADVISORY

NASDAQ: ABVC

Latest News

ABVC NEWSROOM

THERAPEUTIC FOCUS

Retinal Vitrectomy

Vitargus® – ABV-1701
Contact ABVC & Stay Informed

Contact ABVC BioPharma

SOCIAL MEDIA

Facebook

LinkedIn

TELEPHONE

+1 845-291-1291

EMAIL

info@abvcpharma.com

44370 Old Warm Springs Boulevard
Fremont, California 94538 USA
CONTACT FORM

Copyright ©2023 ABVC BioPharma, Inc. All Rights Reserved.

   

Enter your
search terms here.